The American Association for Cancer Research (AACR) is seeking an HCC patient who is currently taking or has taken the combination therapy: tremelimumab + durvalumab (Imjudo + Imfinzi).
AACR would like to conduct a video interview for their annual Cancer Progress Report.
As a token of their appreciation, participants receive Affiliate Membership to AACR as well as a free subscription to Cancer Today, a quarterly magazine geared towards providing information and support for patients and survivors of cancer and their loved ones.
If you or a loved one is interested in sharing your story, please get in touch with Josh Goldstein by email or phone: josh.goldstein@aacr.org or text him at 215-694-6033.
Let him know that Blue Faery's Liver Cancer Community referred you!
Note: This is a volunteer opportunity. There is no honorarium.
#livercancer #combinationtherapy
Updated information causing confusion
Liver cancer metastasis to my lungs incurable 
Experiences with TARE?
Y-90 Plus One Week
